GlassScriptPhysician profile
Nicholas Norris
NPI 1871090688
$2,776.15
in general payments reported to CMS, 2019-2025
12 companies · $73.44 in 2025
The $73.44 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.28 · 2022: $327 · 2023: $382 · 2024: $1,958 · 2025: $73.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392 · Travel and Lodging: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.46 |
| Travel and Lodging | $1,021.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,733.07 | 2024 | Axios, Autotome Rx 49 |
| Abbvie INC. | $260.23 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.96 | 2021-2024 | Gattex |
| Medtronic, INC. | $172.89 | 2023 | Endoflip |
| Chiesi USA, INC. | $130.05 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $72.52 | 2022-2023 | Dupixent |
| Angiodynamics, INC. | $50.78 | 2025 | Alphavac |
| Pharming Healthcare, INC. | $46.88 | 2023-2024 | Ruconest |
| Abiomed | $39.15 | 2024 | Impella |
| Acadia Pharmaceuticals INC | $26.55 | 2023 | Daybue |
| Alcresta Therapeutics, INC. | $25.41 | 2024 | Relizorb |
| Intrabio INC | $22.66 | 2025 | Aqneursa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.